Cargando…

Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)

OBJECTIVES: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. METHODS: We conducted an...

Descripción completa

Detalles Bibliográficos
Autores principales: Beraud, Guillaume, Bouetard, Laura, Civljak, Rok, Michon, Jocelyn, Tulek, Necla, Lejeune, Sophie, Millot, Romain, Garchet-Beaudron, Aurélie, Lefebvre, Maeva, Velikov, Petar, Festou, Benjamin, Abgrall, Sophie, Lizatovic, Ivan K., Baldolli, Aurélie, Esmer, Huseyin, Blanchi, Sophie, Froidevaux, Gabrielle, Kapincheva, Nikol, Faucher, Jean-François, Duvnjak, Mario, Afşar, Elçin, Švitek, Luka, Yarimoglu, Saliha, Yarimoglu, Rafet, Janssen, Cécile, Epaulard, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798780/
https://www.ncbi.nlm.nih.gov/pubmed/36587737
http://dx.doi.org/10.1016/j.cmi.2022.12.020
_version_ 1784860977212162048
author Beraud, Guillaume
Bouetard, Laura
Civljak, Rok
Michon, Jocelyn
Tulek, Necla
Lejeune, Sophie
Millot, Romain
Garchet-Beaudron, Aurélie
Lefebvre, Maeva
Velikov, Petar
Festou, Benjamin
Abgrall, Sophie
Lizatovic, Ivan K.
Baldolli, Aurélie
Esmer, Huseyin
Blanchi, Sophie
Froidevaux, Gabrielle
Kapincheva, Nikol
Faucher, Jean-François
Duvnjak, Mario
Afşar, Elçin
Švitek, Luka
Yarimoglu, Saliha
Yarimoglu, Rafet
Janssen, Cécile
Epaulard, Olivier
author_facet Beraud, Guillaume
Bouetard, Laura
Civljak, Rok
Michon, Jocelyn
Tulek, Necla
Lejeune, Sophie
Millot, Romain
Garchet-Beaudron, Aurélie
Lefebvre, Maeva
Velikov, Petar
Festou, Benjamin
Abgrall, Sophie
Lizatovic, Ivan K.
Baldolli, Aurélie
Esmer, Huseyin
Blanchi, Sophie
Froidevaux, Gabrielle
Kapincheva, Nikol
Faucher, Jean-François
Duvnjak, Mario
Afşar, Elçin
Švitek, Luka
Yarimoglu, Saliha
Yarimoglu, Rafet
Janssen, Cécile
Epaulard, Olivier
author_sort Beraud, Guillaume
collection PubMed
description OBJECTIVES: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. METHODS: We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. RESULTS: Among 1215 patients (median age, 73.0 years; interquartile range, 57.0–84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32–0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26–0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25–0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37–0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12–0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38–0.67]), independent of age, comorbidities, and vaccination status. DISCUSSION: Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics.
format Online
Article
Text
id pubmed-9798780
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-97987802022-12-29 Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) Beraud, Guillaume Bouetard, Laura Civljak, Rok Michon, Jocelyn Tulek, Necla Lejeune, Sophie Millot, Romain Garchet-Beaudron, Aurélie Lefebvre, Maeva Velikov, Petar Festou, Benjamin Abgrall, Sophie Lizatovic, Ivan K. Baldolli, Aurélie Esmer, Huseyin Blanchi, Sophie Froidevaux, Gabrielle Kapincheva, Nikol Faucher, Jean-François Duvnjak, Mario Afşar, Elçin Švitek, Luka Yarimoglu, Saliha Yarimoglu, Rafet Janssen, Cécile Epaulard, Olivier Clin Microbiol Infect Original Article OBJECTIVES: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. METHODS: We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. RESULTS: Among 1215 patients (median age, 73.0 years; interquartile range, 57.0–84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32–0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26–0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25–0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37–0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12–0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38–0.67]), independent of age, comorbidities, and vaccination status. DISCUSSION: Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023-05 2022-12-29 /pmc/articles/PMC9798780/ /pubmed/36587737 http://dx.doi.org/10.1016/j.cmi.2022.12.020 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Beraud, Guillaume
Bouetard, Laura
Civljak, Rok
Michon, Jocelyn
Tulek, Necla
Lejeune, Sophie
Millot, Romain
Garchet-Beaudron, Aurélie
Lefebvre, Maeva
Velikov, Petar
Festou, Benjamin
Abgrall, Sophie
Lizatovic, Ivan K.
Baldolli, Aurélie
Esmer, Huseyin
Blanchi, Sophie
Froidevaux, Gabrielle
Kapincheva, Nikol
Faucher, Jean-François
Duvnjak, Mario
Afşar, Elçin
Švitek, Luka
Yarimoglu, Saliha
Yarimoglu, Rafet
Janssen, Cécile
Epaulard, Olivier
Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
title Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
title_full Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
title_fullStr Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
title_full_unstemmed Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
title_short Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
title_sort impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the omicron variant (b.1.1.529) of the sars-cov-2 (subvariant ba.1)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798780/
https://www.ncbi.nlm.nih.gov/pubmed/36587737
http://dx.doi.org/10.1016/j.cmi.2022.12.020
work_keys_str_mv AT beraudguillaume impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT bouetardlaura impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT civljakrok impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT michonjocelyn impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT tuleknecla impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT lejeunesophie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT millotromain impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT garchetbeaudronaurelie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT lefebvremaeva impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT velikovpetar impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT festoubenjamin impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT abgrallsophie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT lizatovicivank impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT baldolliaurelie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT esmerhuseyin impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT blanchisophie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT froidevauxgabrielle impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT kapinchevanikol impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT faucherjeanfrancois impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT duvnjakmario impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT afsarelcin impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT svitekluka impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT yarimoglusaliha impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT yarimoglurafet impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT janssencecile impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT epaulardolivier impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1
AT impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1